Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

A short-seller published a new analysis that calls some of its clinical trial data into question.

Why Veru Stock Got Dented Today

Several analysts reiterate their bullish outlook on the company.

Why Veru Stock Trounced the Market on Thursday

Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's (NASDAQ: VERU) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes.  The analyst sees the data as "further derisking.

Jefferies Analyst Predicts FDA Emergency Use Nod For Veru's New COVID-19 Therapy In One Month

Veru (VERU) stock is on the move Wednesday after the company published results from its Phase 3 clinical trial of sabizabulin. The post VERU Stock Pops on Clinical Trial Update appeared first on InvestorPlace.

VERU Stock Pops on Clinical Trial Update

It just published great-looking data from a phase 3 clinical trial for its antiviral treatment for severe COVID-19.

Why Veru Stock Is Popping Today

Veru Inc (NASDAQ: VERU) shares are trading higher Wednesday after the company announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for.

Why Veru Stock Is Soaring

- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints -

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

The biotech's experimental oral COVID-19 treatment could be a game changer.

Why Veru Stock Surged Today

Veru Inc (NASDAQ: VERU) has submitted an emergency use authorization (EUA) for sabizabulin application to FDA for COVID-19 treatment. The application covers moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS).

Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment

-- The EUA Submission Follows Positive Phase 3 COVID-19 Clinical Trial in which Sabizabulin Demonstrated a 55.2% Reduction in Death in Hospitalized COVID-19 Patients -- -- The Company is in Discussions with Other Regulatory Agencies Around the World Regarding Emergency Use Authorization for Sabizabulin Including the European Medicines Agency -- -- Company Prepares for U.S. Commercial Launch if EUA is Granted --

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

MIAMI, June 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the final results from the Phase 1b/2 clinical study of sabizabulin, a novel oral cytoskeleton disruptor, in 80 men with metastatic castration resistant prostate cancer (mCRPC) that progressed after receiving at least one androgen receptor targeting agent was presented at a poster session during the 2022 American Society of Clinical Oncology Annual Meeting which is being held June 3-7, 2022.

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will be presenting three presentations at the 2022 American Society of Clinical Oncology Annual Meeting which will be held in Chicago, IL from June 3-7, 2022.

Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7

An Emergency Use Authorization submission of sabizabulin for high-risk hospitalized Covid-19 patients is expected Q2 of 2022. With EUA and then possibly NDA occurring for sabizabulin, Veru would be in a good position to develop advance purchase orders with several Government agencies around the world.

Veru: On Right Track For FDA EUA Submission

Veru Inc is a Florida-based drug developer, which focuses primarily on developing cancer-treatment drugs as well as its sexual health division. This year, the company hit a stroke of luck upon discovering its cancer treatment candidate, Sabizabulin is a highly efficacious and safe treatment against ARDS in later-stage Covid-19 patients.

Veru Inc. Still Has Serious Growth To Realize

Veru (VERU) stock is on the move Wednesday following news of the biopharmaceutical company adding Joel Batten to its list of executives. The post VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive appeared first on InvestorPlace.

VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive

MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022.

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

Shares of companies in the broader consumer staples sector, including Veru Inc (NASDAQ: VERU), are trading higher as stocks rebound from recent weakness. Stocks have experienced volatility this year amid Fed policy tightening measures.

So What's Up With Veru Shares Rising Today?

VERU stock's rapid upward trajectory could continue as Veru releases its fiscal results and marks a significant clinical milestone. The post Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise appeared first on InvestorPlace.

Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise

Veru's Sabizabulin showed superlative results in critically ill COVID patients. No other drug has been able to achieve this.

Veru: Where Big Pharma Failed To Tread

MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the H.C. Wainwright Global Investment Conference. The presentation will be available through the Conference on Tuesday, May 24th at 11:30 AM – 12:00 PM (Eastern Daylight Time).

Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022

Eliem Therapeutics

Vertex Energy

Camping World Hlds

Medavail Holdings Inc

Short squeeze stocks are once again in focus this week as the bears continue to run wild in the stock market. The post Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

Call End: Veru Inc. (NASDAQ:VERU ) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Howerton - Jefferies Leland Gershell - Oppenheimer Yi Chen - H.C. Wainwright Kumar Raja - Brookline Capital Markets Operator Good morning, ladies and gentlemen, and welcome to Veru Incorporated Investor Conference Call.

Veru Inc.'s (VERU) CEO Mitchell Steiner on Q2 2022 Results - Earnings Call Transcript

Veru Inc. (VERU) delivered earnings and revenue surprises of -12.50% and 14.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates

--FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients-- --IDMC Unanimously Votes to Halt the Ongoing Phase 3 Trial of Sabizabulin for Hospitalized COVID-19 Patients at High Risk of ARDS Due to Overwhelming Efficacy and Safety with 55.2% Reduction in Death--

News for Veru Stock (VERU)